Defy Medical vs Maximus: Premium MD-Led Clinic vs Fertility-Preserving Oral Protocol
Defy Medical and Maximus serve overlapping audiences (TRT users seeking protocol customization beyond standard monotherapy) with very different approaches. Defy is a 16-year-old Tampa clinic with MD/DO physicians and willingness to customize protocols (HCG, anastrozole, non-standard dosing). Maximus runs the only TRT provider in our cohort with a publicly-documented clinical study on its protocol, focused on fertility-preserving oral testosterone + enclomiphene. The choice depends on whether you want physician-led protocol depth or a structurally different protocol designed around fertility preservation.
Defy Medical
3.6Established Tampa hormone clinic with MD/DO physicians and premium pricing
Maximus
3.1Fertility-preserving oral TRT with enclomiphene; published clinical study, but BBB F rating with unanswered complaints
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
Defy Medical for users who want traditional TRT with physician-led protocol customization and are willing to pay premium prices for it. Maximus for users who specifically want fertility-preserving oral TRT and have read the BBB complaint pattern. Neither is the cohort default for most users (Hone Health is); this comparison is for users specifically choosing between premium physician depth and protocol differentiation.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
BBB rating and complaint posture
Winner: Defy MedicalDefy carries a BBB C rating with one unanswered complaint despite being a 16-year-old clinic. Maximus carries an F rating driven by unanswered complaints documenting repeat charges without medication delivery and refund refusals. Both are imperfect; Defy's C is materially better than Maximus's F.
Operational track record
Winner: Defy MedicalDefy has been operating since 2009, 16 years of operational tenure. Maximus is a younger entrant with a much shorter track record and the documented complaint pattern. For risk-averse users, Defy's longer history is the cleaner choice.
Physician credentials and protocol customization
Winner: Defy MedicalDefy uses MDs and DOs with documented endocrinology and hormone-optimization backgrounds, with willingness to customize beyond standard monotherapy (HCG, anastrozole, non-standard dosing). ExcelMale forum threads cite individual Defy physicians by name. Maximus has board-certified physicians but the protocols are more standardized into the published study tiers.
Published clinical study evidence
Winner: MaximusMaximus is the only TRT provider in our cohort with a publicly-documented clinical study on its specific protocol. Defy is well-respected for physician quality but does not market a comparable published-study evidence base for its protocols.
Fertility preservation
Winner: MaximusMaximus's Oral T + Enclomiphene protocol preserves LH/FSH within normal ranges. Defy is willing to add HCG to traditional injectable TRT to preserve fertility markers, but that requires the physician relationship and additional cost; Maximus's flagship protocol bakes fertility preservation in by default.
All-in monthly cost
Winner: MaximusMaximus enclomiphene-only at $99.99/mo on annual commitment is materially below Defy's $200-$350/mo medication plus $200-$400 per quarterly lab panel. Even Maximus's Oral T + Enclomiphene at $199.99/mo annual is meaningfully cheaper than Defy. Defy wins on physician depth; Maximus wins on cost.
Refill reliability
Winner: MaximusDefy has multiple ExcelMale forum threads documenting refill delays of up to two weeks. Maximus has BBB-documented complaint patterns that include cancellation friction but the refill-delay pattern is less consistent than Defy's documented two-week refill issues. Maximus wins this row by a smaller margin; both have operational issues, just different shapes.
Insurance and pharmacy flexibility
Winner: MaximusDefy will not fax prescriptions to outside pharmacies, blocking insurance routing. Maximus has its own caveats (annual-commitment structure) but does not impose comparable pharmacy restrictions. Neither accepts insurance directly (cash-pay is standard in TRT telehealth).
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
Defy: $149-$350 initial consult + $200-$350/mo medication + $200-$400 per quarterly lab panel via LabCorp ($300-$450/mo effective). Maximus: $99.99/mo enclomiphene-only or $199.99/mo Oral T + Enclomiphene on annual commitment. Maximus is materially cheaper; Defy is materially more expensive but buys physician-led protocol depth. The pricing gap is large enough that for users who want the Defy physician relationship, the price is the cost of admission.
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.